Xylem Inc. (XYL) SEC Filings & Earnings Calls
EquiReason read 15 Xylem Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-09-29 — Xylem Inc. files underwriting agreement and supplemental indenture for issuance of 5.250% Senior Notes due 2029, 5.450% Senior Notes due 2032, and 5.850% Senior Notes due 2037..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 25.4B
- P/E TTM
- 25.9
- Dividend yield
- 1.5%
- 52-week
- —
- Next earnings
- 27 Oct, in 3 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
9 Sep 20268-K · 1.01, 1.02, 2.03Xylem entered a $1.5B senior unsecured revolving credit facility (expandable to $2B), replacing a $1B facility. No borrowings outstanding. Used for working capital and general corporate purposes.open
Risks flagged
No borrowings outstanding; facility used for general corporate purposes
“No borrowings are outstanding under the 2026 Credit Agreement on the date hereof” · word for word
18 Aug 20268-K · 5.02, 7.01Guidance: Reaffirmed Q3 and full-year 2026 guidanceopen
Guidance
Reaffirmed Q3 and full-year 2026 guidance
Company reaffirms previously issued guidance for Q3 and full year 2026, indicating stability.
Risks flagged
Transition risk from CFO departure, though mitigated by internal promotion and orderly transition
“CFO resignation to pursue other opportunity; transition period through mid-September”
28 Jul 202610-QXylem reported Q2 2026 revenue of $2.336B (+1.5% YoY), orders surged 42%, gross margin expanded 240bps, and backlog grew 5.9% YoY.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $2.34B | +2% y/y |
| Net income attributable to Xylem · Q2-2026 | $263M | +16% y/y |
| Operating cash flow · H1-2026 | $398M | +18% y/y |
| Backlog · 2026-06-30 | $5.32B | +6% y/y |
| Orders · Q2-2026 | $3.09B | +42% y/y |
| Gross margin · Q2-2026 | 41.2% | |
| Adjusted EBITDA margin · Q2-2026 | 23.3% | |
| Free cash flow · H1-2026 | $219M | +30% y/y |
Risks flagged
Inflation pressure on margins
“240 basis points of inflation” · word for word
Measurement and Control Solutions segment decline
“Measurement and Control Solutions revenue decreased $32 million, or 5.9%... organic revenue declines were driven by $7 million from the smart metering and other applications.” · word for word
Divestiture impact on revenue
“loss of revenue from divestitures of $31 million” · word for word
28 Jul 20268-K · 2.02Xylem Q2 2026: revenue $2.3B (+2% reported, +1% organic), EPS $1.11 (+19%), adj. EPS $1.46 (+16%), orders $3.1B (+42%). FY26 guidance: revenue ~$9.2B (prev. 2-3% growth now ~2%), adj. EBITDA margin 23.1-23.5%, adj. EPS $5.55-$5.70 (raised fearningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $2.30B | +2% y/y |
| Orders · Q2-2026 | $3.10B | +42% y/y |
| Earnings per share · Q2-2026 | $1.11 | +19% y/y |
| Adjusted earnings per share · Q2-2026 | $1.46 | +16% y/y |
| Net income · Q2-2026 | $263M | |
| Net income margin · Q2-2026 | 11.3% | |
| Adjusted EBITDA margin · Q2-2026 | 23.3% | |
| Adjusted net income · Q2-2026 | $345M |
Guidance
FY26 revenue ~$9.2B (~2% reported, 2-3% organic vs prior 2-3% and 2-4%); FY26 adj. EBITDA margin 23.1-23.5% (90-130 bps expansion); FY26 adj. EPS $5.55-$5.70 (raised from $5.35-$5.60); FY26 free cash flow margin 10.2-11.0% (unchanged)
Xylem raised FY26 adjusted EPS guidance and narrowed revenue guidance, while expanding EBITDA margin expectations. Strong demand from AI infrastructure and industrial markets supports positive outlook.
Risks flagged
Lower volumes partially offset margin expansion, indicating some demand softness in certain areas.
“Productivity savings, strong price realization and mix drove the margin expansion, exceeding the impact of inflation and lower volumes.” · word for word
Increased income tax expense and loss on sale of businesses partially offset strong operational performance.
“Partially offset by increased income tax expense and loss on sale of businesses.” · word for word
28 Apr 20268-K · 2.02Revenue $2.10B (+3% y/y); Orders $2.20B (+3% y/y); Earnings Per Share (GAAP) $0.79 (+14% y/y); Guidance: FY revenue guidance raised to ~$9.2-$9.3B (from 1-3% reported to 2-3%); adj. EPS unchanged $5.35-$5.60earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $2.10B | +3% y/y |
| Orders · Q1-2026 | $2.20B | +3% y/y |
| Earnings Per Share (GAAP) · Q1-2026 | $0.79 | +14% y/y |
| Adjusted Earnings Per Share · Q1-2026 | $1.12 | +9% y/y |
| Net Income Attributable to Xylem · Q1-2026 | $193M | |
| Adjusted Net Income Attributable to Xylem · Q1-2026 | $272M | |
| Adjusted EBITDA Margin · Q1-2026 | 20.6% |
Guidance
FY revenue guidance raised to ~$9.2-$9.3B (from 1-3% reported to 2-3%); adj. EPS unchanged $5.35-$5.60
Xylem raised full-year revenue guidance slightly while maintaining EPS and margin guidance; Q1 execution solid.
Risks flagged
Organic revenue growth flat in Q1; macro uncertainty could impact future demand.
“Revenue of $2.1 billion, up 3% on a reported basis and flat organically.”
28 Apr 202610-QRevenue $2.12B (+3% y/y); Net income attributable to Xylem $193M (+14% y/y); Adjusted EBITDA $437M (+3% y/y); Guidance: total revenue growth outlook raised to 2% to 3% (from prior); organic revenue growth maintained at 2% to 4%open
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $2.13B | +3% y/y |
| Net income attributable to Xylem · Q1-2026 | $193M | +14% y/y |
| Adjusted EBITDA · Q1-2026 | $437M | +3% y/y |
| Orders · Q1-2026 | $2.23B | +3% y/y |
| Backlog · 2026-03-31 | $4.71B | -8% y/y |
| Gross margin · Q1-2026 | 37.8% | |
| Adjusted EBITDA margin · Q1-2026 | 20.6% | |
| Free cash flow · Q1-2026 | $18M | |
| Operating cash flow · Q1-2026 | $108M | +227% y/y |
Guidance
total revenue growth outlook raised to 2% to 3% (from prior); organic revenue growth maintained at 2% to 4%
Xylem raised its total revenue growth outlook to 2-3% while maintaining organic revenue growth guidance of 2-4%, reflecting confidence despite macro uncertainty.
Risks flagged
Tariff uncertainty and potential refunds
“As of March 31, 2026, we have not recorded a receivable related to potential tariff refunds due to the uncertainty regarding the timing and amount of such refunds at this time.” · word for word
Geopolitical and trade uncertainty
“Our outlook is being provided in the context of the current volatility, including due to geopolitical, trade, macroeconomic and regulatory uncertainty.” · word for word
30 Mar 2026DEF 14AXylem filed its 2026 Proxy Statement (DEF 14A), disclosing executive compensation, governance, and 2025 performance highlights.open
Figures in the filing · each found in the filing text
| Revenue · FY2025 | $9.04B | +6% y/y |
| Net Income · FY2025 | $957M | +8% y/y |
| Adjusted EBITDA Margin · FY2025 | 22.2% | |
| Backlog · FY2025 | $4.60B | |
| Orders · FY2025 | $8.90B | |
| Adjusted EPS · FY2025 | $5.08 | +19% y/y |
| Operating Cash Flow Margin · FY2025 | 13.7% | |
| Adjusted Free Cash Flow Margin · FY2025 | 10.2% |
Risks flagged
Integration and transformation execution risk
“Transformation will continue as we execute our ERP program, accelerate our 80/20 initiatives, and make thoughtful moves to optimize our portfolio.” · word for word
Macroeconomic and demand uncertainty
“A detailed discussion of risks and uncertainties that could cause actual results and events to differ materially from such forward-looking statements is included in 'Item 1A. Risk Factors'” · word for word
25 Feb 202610-KRevenue $9.04B (+6% y/y); Net income attributable to Xylem $957M (+8% y/y); Adjusted earnings per share $5.08 (+19% y/y); Guidance: Backlog $4,615M; ~60% expected to convert to revenue in 2026. Restructuring savings $80-120M expected in 202open
Figures in the filing · each found in the filing text
| Revenue · FY2025 | $9.04B | +6% y/y |
| Net income attributable to Xylem · FY2025 | $957M | +8% y/y |
| Adjusted earnings per share · FY2025 | $5.08 | +19% y/y |
| Adjusted operating margin · FY2025 | 17.8% | |
| Gross margin · FY2025 | 38.5% | |
| Orders · FY2025 | $8.90B | +2% y/y |
| Backlog · FY2025 | $4.62B | -9% y/y |
| Adjusted EBITDA · FY2025 | $2.01B | +14% y/y |
| Free cash flow · FY2025 | $910M | -3% y/y |
| Capital expenditures · FY2025 | $331M | +3% y/y |
Guidance
Backlog $4,615M; ~60% expected to convert to revenue in 2026. Restructuring savings $80-120M expected in 2026.
Backlog decline suggests near-term revenue headwind, but restructuring savings and margin expansion provide offset. Management tone positive based on strong margin performance and dividend increase.
Risks flagged
Tariff exposure on imported inputs
“While we may recover some cost increases through operational improvements, we are still exposed to pricing risk, including due to duty and tariff assessments by the U.S. or other governments on foreign imports.” · word for word
Backlog decline
“Total backlog was $4,615 million at December 31, 2025 and $5,070 million at December 31, 2024, a decrease of 9.0%.” · word for word
Emerging markets softness
“Organic growth in the U.S. and western Europe more than offsetting organic declines in the emerging markets.” · word for word
10 Feb 20268-K · 2.02Revenue $2.40B (+6% y/y); Adjusted earnings per share $1.42 (+20% y/y); Orders $2.40B (+9% y/y); Guidance: 2026 revenue guidance $9.1-9.2B (+2-4% organic), adj. EPS $5.35-5.60earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q4-2025 | $2.40B | +6% y/y |
| Adjusted earnings per share · Q4-2025 | $1.42 | +20% y/y |
| Orders · Q4-2025 | $2.40B | +9% y/y |
| Adjusted EBITDA margin · Q4-2025 | 23.2% | |
| Dividend per share · Q1-2026 | $0.43 | +8% y/y |
| Full-year revenue · FY2025 | $9.00B | +6% y/y |
| Full-year adjusted EPS · FY2025 | $5.08 | +19% y/y |
Guidance
2026 revenue guidance $9.1-9.2B (+2-4% organic), adj. EPS $5.35-5.60
Positive 2026 guidance with organic revenue growth of 2-4%, adjusted EBITDA margin expansion of 70-110bps, and free cash flow margin of 10.2-11%
Risks flagged
Tariff and macroeconomic headwinds: inflation, energy supply, supply chain shortages mentioned as risk factors
“manufacturing and operating cost increases due to macroeconomic conditions, including inflation, energy supply, supply chain shortages, logistics” · word for word
28 Oct 20258-K · 2.02Revenue $2.30B (+8% y/y); Earnings per share $0.93 (+4% y/y); Adjusted earnings per share $1.37 (+23% y/y); Guidance: Revenue guidance raised to ~$9.0B (5-6% reported vs prior 4-5%); adjusted EPS raised to $5.03-$5.08 from $4.70-$4.85earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q3-2025 | $2.30B | +8% y/y |
| Earnings per share · Q3-2025 | $0.93 | +4% y/y |
| Adjusted earnings per share · Q3-2025 | $1.37 | +23% y/y |
| Adjusted EBITDA margin · Q3-2025 | 23.2% | |
| Net income · Q3-2025 | $227M | |
| Full-year 2025 revenue guidance · FY2025 | $9.00B | |
| Full-year 2025 adjusted EPS guidance · FY2025 | $5.05 |
Guidance
Revenue guidance raised to ~$9.0B (5-6% reported vs prior 4-5%); adjusted EPS raised to $5.03-$5.08 from $4.70-$4.85
Raised full-year guidance on resilient demand and strong execution, with margin expansion driving EPS growth.
Risks flagged
Geopolitical, trade, macroeconomic, and regulatory uncertainty could impact future performance.
“Outlook is being provided in the context of the current volatility, including due to geopolitical, trade, macroeconomic and regulatory uncertainty.” · word for word
28 Oct 202510-QQ3 2025 revenue grew 7.8% YoY to $2.27B, gross margin expanded 160bps to 38.9%, and adjusted EBITDA margin improved 200bps to 23.2%.earningsopen
Figures in the filing · each found in the filing text
| Total Revenue · Q3-2025 | $2.27B | +8% y/y |
| Organic Revenue Growth · Q3-2025 | 6.9% | |
| Orders · Q3-2025 | $2.18B | -1% y/y |
| Backlog · 2025-09-30 | $4.82B | -8% y/y |
| Gross Margin · Q3-2025 | 38.9% | |
| Operating Income · Q3-2025 | $334M | +19% y/y |
| Net Income Attributable to Xylem · Q3-2025 | $227M | +5% y/y |
| Adjusted EBITDA Margin · Q3-2025 | 23.2% | |
| Adjusted Earnings Per Share · Q3-2025 | $1.37 | +23% y/y |
| Operating Cash Flow (YTD) · 9M-2025 | $698M | +2% y/y |
Risks flagged
Order Softness in Emerging Markets
“Organic growth for the transport application was $42 million, led by higher volume in the U.S., and strong backlog execution and order intake in western Europe. (Emerging markets softness noted in multiple segments)” · word for word
Backlog Decline
“Total backlog was $4,819 million at September 30, 2025, a decrease of $434 million, or 8.3%, as compared to September 30, 2024 backlog of $5,253 million.” · word for word
Restructuring Execution Risk
“We currently expect to incur between $90 and $100 million in restructuring costs for the full year.” · word for word
Xylem Inc. — questions
- What did Xylem Inc. file recently?
- 15 SEC filings in the last 12 months. Latest: 8-K on 2026-09-29 — Xylem Inc. files underwriting agreement and supplemental indenture for issuance of 5.250% Senior Notes due 2029, 5.450% Senior Notes due 2032, and 5.850% Senior Notes due 2037.
Every figure on this page comes from Xylem Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.